Metastatic Melanoma and Vemurafenib: Novel Approaches | Zendy

Ramon Andrade de Mello | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metastatic Melanoma and Vemurafenib: Novel Approaches

Author(s) -

Ramon Andrade de Mello

Publication year - 2012

Publication title -

rare tumors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.285

H-Index - 15

eISSN - 2036-3613

pISSN - 2036-3605

DOI - 10.4081/rt.2012.e31

Subject(s) - vemurafenib , medicine , dacarbazine , metastatic melanoma , melanoma , cancer research , oncology , mutation , first line , dermatology , gene , biochemistry , chemistry

Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase inhibitor that showed impressive results in phase I-III trials and was thus recently approved for the treatment of MM. This paper will briefly focus on vemurafenib in the treatment of MM and highlight concerns

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research